🔴 Citius Pharmaceuticals is trading 6.6% down with no clear company-specific catalyst

Citius Pharmaceuticals is trading at $0.46, down -6.64%, with no clear company-specific announcement explaining the decline.

• The latest company news found was an October 12 investor-conference announcement.
• A recent report said the FDA’s Lymphir decision required enhanced product testing, but available coverage does not establish that it caused the October 13 move.
• Healthcare-sector weakness may have added pressure; broader market indexes were down only modestly in the supplied context.